SUBSCRIBE
SUBSCRIBE

IgA nephropathy

Entrance to Vertex's office in Boston, Massachusetts
Deals
Vertex Buys Alpine for $4.9B to Bolster Autoimmune and Inflammatory Disease Pipeline
Vertex Pharmaceuticals on Wednesday announced it is acquiring clinical-stage immunotherapy company Alpine Immune Sciences for $4.9 billion in cash, the largest acquisition so far this year.
April 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
July 9, 2025
 · 
3 min read
Press Releases
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
July 1, 2025
 · 
18 min read
Press Releases
BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria
June 26, 2025
 · 
4 min read
Press Releases
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
June 23, 2025
 · 
10 min read
Press Releases
Ono Pharmaceutical and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
June 23, 2025
 · 
10 min read
Press Releases
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
June 9, 2025
 · 
10 min read
Press Releases
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
June 6, 2025
 · 
10 min read
Press Releases
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress
June 4, 2025
 · 
17 min read
Press Releases
Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress
June 2, 2025
 · 
5 min read
Press Releases
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
June 2, 2025
 · 
8 min read
England’s NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
May 23, 2025
 · 
9 min read
Press Releases
Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
May 13, 2025
 · 
17 min read
Press Releases
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
April 29, 2025
 · 
6 min read
Press Releases
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
April 29, 2025
 · 
7 min read
Press Releases
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
April 28, 2025
 · 
4 min read
Press Releases
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
April 4, 2025
 · 
6 min read
Press Releases
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
April 3, 2025
 · 
21 min read
Press Releases
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
April 1, 2025
 · 
9 min read
Press Releases
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
March 26, 2025
 · 
12 min read
Press Releases
Purespring Therapeutics appoints Haseeb Ahmad as Chief Executive Officer
March 12, 2025
 · 
5 min read
Load More